This is a rare genetic condition where your kidneys produce too much oxalate. Oxalate is a type of salt that can build up in your urine and form kidney stones. It can also lead to calcium oxalate kidney stones and sometimes kidney failure over time.
Every report comes from a Lived member, sent anonymously.
Have you tried Vitamin B6 for Primary Hyperoxaluria?
Primary hyperoxaluria is a group of rare inherited conditions in which the liver makes far too much oxalate, a waste product the body cannot break down and must clear through the urine. As that oxalate passes through the kidneys, it binds with calcium to form calcium oxalate, the hard material in most kidney stones. The result is repeated kidney and bladder stones, along with calcium oxalate deposits inside the kidney tissue itself, called nephrocalcinosis. Over years, these crystals can scar the kidneys and reduce how well they work. Once kidney function falls far enough, oxalate builds up in the blood and settles elsewhere in the body, including the bones, blood vessels, heart, skin and eyes. This widespread stage is called systemic oxalosis, and preventing it is one of the main goals of care. There are three known types. Type 1 accounts for about 80 percent of cases and is usually the most severe. Types 2 and 3 each make up roughly 10 percent: type 2 tends to cause kidney failure later in life, and type 3 is generally the mildest, mainly causing stones that start in childhood. Primary hyperoxaluria is different from the more common secondary hyperoxaluria, in which high oxalate comes from bowel disease, weight-loss surgery, diet or supplements rather than an inherited enzyme problem.
Primary hyperoxaluria is caused by changes in one of three genes: AGXT (type 1), GRHPR (type 2) or HOGA1 (type 3). Each gene carries the instructions for an enzyme, mainly active in the liver, that helps process glyoxylate, a chemical made during normal metabolism. When the enzyme is missing or does not work, more glyoxylate is turned into oxalate, and the liver keeps producing it regardless of what a person eats. The condition is inherited in an autosomal recessive pattern, meaning a person is affected only when they inherit a nonworking copy of the same gene from each parent. Parents who each carry one copy usually have no symptoms, and carriers generally have normal oxalate levels. When both parents are carriers, each child has a 1 in 4 chance of being affected. The condition is more common in communities where parents are more often blood relatives. Nothing a person does causes primary hyperoxaluria, and how severe it becomes varies widely, even among relatives with the same type. Some everyday factors can still make stones more likely to form. Becoming dehydrated concentrates the urine, large doses of vitamin C can raise oxalate further, and specialists also advise against large doses of vitamin D.
Primary hyperoxaluria is often recognized late, because kidney stones are common and early episodes may be treated as ordinary stones or urinary infections. It should be considered when stones begin in childhood or adolescence, keep coming back, or appear with nephrocalcinosis, when kidney function declines without a clear reason, or when relatives have had stones or kidney failure. Some adults are diagnosed only after their kidney function is already reduced, and occasionally only after a kidney transplant fails because the disease returns in the new kidney. The key first test is a 24-hour urine collection to measure oxalate, adjusted for body size. In healthy people the daily amount is below about 0.5 millimoles (per 1.73 square meters of body surface, the standard adjustment), while most people with primary hyperoxaluria pass more than 1, at least twice the normal upper limit. A high result should be confirmed on at least two collections, and doctors check for secondary causes such as bowel disease, weight-loss surgery or high vitamin C intake. When kidney function is reduced, 24-hour results become less reliable, so doctors rely more on a urine oxalate-to-creatinine ratio and on blood oxalate levels. Genetic testing confirms the diagnosis and identifies the type. That matters because treatments differ by type, and some type 1 gene changes predict a response to vitamin B6. Once one person is diagnosed, brothers and sisters are usually offered testing, since they can have high oxalate before any symptoms. Ultrasound, which uses no radiation, is the usual first scan for stones and nephrocalcinosis, and X-rays or a computed tomography (CT) scan can add detail. Analysis of a passed or removed stone also helps, since these stones are typically almost pure calcium oxalate monohydrate. A liver biopsy to measure enzyme activity is now rarely needed.
Treatment aims to reduce the oxalate reaching the kidneys, keep it from crystallizing, protect kidney function and prevent oxalate from building up elsewhere in the body. The plan depends on the type, how well the kidneys work and how a person responds, and is usually led by a kidney specialist (nephrologist) with experience in the condition. Everyone with the condition needs very dilute urine. That usually means drinking far more than ordinary advice suggests: often 3.5 to 4 liters a day for adults (roughly 15 to 17 cups), with targets for children set by body size. Some infants need a feeding tube into the stomach (gastrostomy) to get enough fluid. Potassium citrate, taken by mouth, is commonly added to help keep calcium oxalate from crystallizing, although the evidence for it is limited. A strict low-oxalate diet is not usually advised, because most oxalate comes from the liver rather than food; avoiding very high-oxalate foods such as spinach, rhubarb, chocolate and nuts is the usual approach. These measures help, but on their own they often do not prevent stones or kidney decline. For type 1, vitamin B6 (pyridoxine) is usually tried early, because some people, particularly those with certain AGXT gene changes, make substantially less oxalate while taking it. Repeat urine tests over weeks to months show whether it is working. It is taken at a prescribed dose, since very high doses can damage nerves without adding benefit. Two injected medicines now treat type 1 by turning down a different liver enzyme earlier in the chain that produces oxalate. Both are RNA interference (RNAi) drugs: they block the RNA, the working copy of a gene's instructions, that cells use to make a specific enzyme. Lumasiran (Oxlumo) is approved for children and adults, including infants and people on dialysis; it starts with three monthly injections under the skin and then continues every three months (monthly for the smallest infants). Nedosiran (Rivfloza) is a monthly injection approved for people 2 and older with type 1 whose kidney function is still relatively preserved. In trials, both lowered urine oxalate substantially, and many people reached normal or near-normal levels. The most common side effect is a reaction where the injection was given. The evidence so far rests mainly on oxalate measurements over a few years; whether these drugs prevent kidney failure over a lifetime is still being studied. Nedosiran did not help type 2, and data for type 3 are early. Stones that block urine flow or keep causing problems are removed, usually by ureteroscopy, in which a thin scope passed up the urinary tract breaks the stone with a laser. Shock-wave treatment from outside the body is used less often, because these stones are unusually hard and the kidneys may already be fragile. When kidney failure develops, standard dialysis cannot remove oxalate as fast as the body makes it, so people often need more frequent hemodialysis, sometimes daily; peritoneal dialysis is not recommended. For type 1, a liver transplant is the only treatment that corrects the underlying problem, because the liver is where the faulty enzyme works. People with type 1 and advanced kidney failure usually need a combined liver and kidney transplant, since a new kidney on its own tends to be damaged by the oxalate the liver keeps making. A kidney transplant alone may be reasonable in selected people whose oxalate is well controlled, such as strong vitamin B6 responders. Any transplant means lifelong medicines that suppress the immune system. The newer drugs may change whether and when transplants are needed, and transplant decisions for type 2 are made case by case.
Primary hyperoxaluria is lifelong, and its course varies greatly, even within one family. Most people with type 1 have symptoms in childhood or early adolescence, and before the newer medicines, kidney failure typically developed in early to middle adulthood, though it can happen at any age. A severe infant form, seen almost only in type 1, can cause kidney failure in the first year of life. Type 2 usually progresses more slowly, and type 3 rarely leads to kidney failure, although stones can continue into adulthood. Day to day, the condition revolves around fluid. Drinking large amounts on a steady schedule becomes a routine for the person and, for a child, the whole family, and it matters even more during hot weather, exercise and illness. Medicines by mouth and, for many people with type 1, injections every month or every three months become part of ordinary life, and RNAi treatment is generally expected to continue long term. Follow-up is regular: urine and blood oxalate tests to judge whether treatment is working, often at least twice a year once things are stable, along with kidney function tests and periodic ultrasounds to look for new stones. Earlier diagnosis and the newer medicines aim to keep oxalate low before lasting kidney damage occurs, but long-term outcomes with these drugs are still being gathered. Genetic counseling can help families understand the chance that other children are affected.
Ask about testing for primary hyperoxaluria if kidney stones began in childhood or adolescence, keep recurring, or come with nephrocalcinosis or unexplained loss of kidney function, or if a brother, sister or parent has the condition. If you already have the condition, contact your care team promptly when vomiting, diarrhea or another illness keeps you from drinking your usual amount, since dehydration quickly concentrates the urine. Severe side or back pain that won't settle, fever or chills with stone pain, or passing little or no urine can mean a stone is blocking a kidney, possibly with infection, and needs emergency care.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Primary Hyperoxaluria is like, what's helped you, or ask the community a question.